Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
Immune checkpoint inhibition has been approved for front-line treatment of metastatic bladder cancer in patients who are cisplatin-ineligible and demonstrate programmed death-ligand 1 (PD-L1) positivity. This approval followed the positive results of IMvigor210 and KEYNOTE-052 studies. Immunotherapy...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-04-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/17562872211004797 |